Oncotype DX in women and men with ER-positive HER2-negative early stage breast cancer Who are lymph node-positive: a review of clinical effectiveness and guidelines
CADTH
Record ID 32014000832
English
Authors' recommendations:
At present, the evidence base for the use of Oncotype DX in the population of early invasive breast cancer that is ER+, HER2-, and LN+ for guiding treatment decisions in the adjuvant setting is very limited and further restricted to women. Guidelines on the use of Oncotype DX in clinical practice were limited to a few general statements about molecular testing.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/mar-2014/RC0517_OncotypeDX_NodePos%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Breast Neoplasms
- Breast Neoplasms, Male
- Gene Expression Profiling
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.